Literature DB >> 10102689

Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes.

M Y Donath1, D J Gross, E Cerasi, N Kaiser.   

Abstract

The gerbil Psammomys obesus develops nutrition-dependent diabetes associated with moderate obesity. The disease is characterized by initial hyperinsulinemia, progressing to hypoinsulinemia associated with depleted pancreatic insulin stores. The contribution of changes in beta-cell turnover to insulin deficiency was investigated in vivo during transition to overt diabetes. Normo glycemic diabetes-prone P. obesus animals who were given a high-calorie diet developed hyperglycemia within 4 days, which was found to be associated with a progressive decline in pancreatic insulin content. This was accompanied by a transient increase in beta-cell proliferative activity and by a prolonged increase in the rate of beta-cell death, culminating in disruption of islet architecture. The hypothesis that "glucotoxicity" was responsible for these in vivo changes was investigated in vitro in primary islet cultures. Exposure of islets from diabetes-prone P. obesus to high glucose levels resulted in a dose-dependent increase in beta-cell DNA fragmentation. In contrast, high glucose levels did not induce DNA fragmentation in rat islets, whereas islets from a diabetes-resistant P. obesus line exhibited a reduced and delayed response. Aminoguanidine did not prevent glucose-induced beta-cell DNA fragmentation in vitro, suggesting that formation of nitric oxide and/or advanced glycation end products plays no major role. Elevated glucose concentrations stimulated beta-cell proliferation in both rat and P. obesus islets. However, unlike the marked long-lasting effect in rat islets, only a transient and reduced proliferative response was observed in P. obesus islets; furthermore, beta-cell proliferation was inhibited after prolonged exposure to elevated glucose levels. These results suggest that hyperglycemia-induced beta-cell death coupled with reduced proliferative capacity may contribute to the insulin deficiency and deterioration of glucose homeostasis in P. obesus. Similar adverse effects of hyperglycemia could play a role in the evolution of type 2 diabetes in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102689     DOI: 10.2337/diabetes.48.4.738

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  101 in total

1.  Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells.

Authors:  Nurit Kaiser; Rafael Nesher; Andrei Oprescu; Suad Efendic; Erol Cerasi
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Hyperglycemia induces apoptosis and p53 mobilization to mitochondria in RINm5F cells.

Authors:  C Ortega-Camarillo; A M Guzmán-Grenfell; R García-Macedo; A M Rosales-Torres; A Avalos-Rodríguez; G Durán-Reyes; R Medina-Navarro; M Cruz; M Díaz-Flores; J Kumate
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

4.  Insulin resistance is a risk factor for progression to type 1 diabetes.

Authors:  S Fourlanos; P Narendran; G B Byrnes; P G Colman; L C Harrison
Journal:  Diabetologia       Date:  2004-10-06       Impact factor: 10.122

5.  Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets.

Authors:  Lara Bellini; Mélanie Campana; Claude Rouch; Marta Chacinska; Marco Bugliani; Kelly Meneyrol; Isabelle Hainault; Véronique Lenoir; Jessica Denom; Julien Véret; Nadim Kassis; Bernard Thorens; Mark Ibberson; Piero Marchetti; Agnieszka Blachnio-Zabielska; Céline Cruciani-Guglielmacci; Carina Prip-Buus; Christophe Magnan; Hervé Le Stunff
Journal:  Diabetologia       Date:  2018-05-12       Impact factor: 10.122

6.  Hyperglycemia promotes p53-Mdm2 interaction but reduces p53 ubiquitination in RINm5F cells.

Authors:  R Barzalobre-Gerónimo; Barzalobre-Gerónimo Raúl; L A Flores-López; Flores-López Luis Antonio; L A Baiza-Gutman; Baiza-Gutman Luis Arturo; M Cruz; Cruz Miguel; R García-Macedo; García-Macedo Rebeca; A Ávalos-Rodríguez; Ávalos-Rodríguez Alejandro; A Contreras-Ramos; Contreras-Ramos Alejandra; A Díaz-Flores; Díaz-Flores Margarita; C Ortega-Camarillo; Ortega-Camarillo Clara
Journal:  Mol Cell Biochem       Date:  2015-04-28       Impact factor: 3.396

Review 7.  Expansion of beta-cell mass in response to pregnancy.

Authors:  Sebastian Rieck; Klaus H Kaestner
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

8.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

Authors:  Marianne Böni-Schnetzler; Jeffrey Thorne; Géraldine Parnaud; Lorella Marselli; Jan A Ehses; Julie Kerr-Conte; Francois Pattou; Philippe A Halban; Gordon C Weir; Marc Y Donath
Journal:  J Clin Endocrinol Metab       Date:  2008-07-29       Impact factor: 5.958

9.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta.

Authors:  Robert S Garofalo; Stephen J Orena; Kristina Rafidi; Anthony J Torchia; Jeffrey L Stock; Audrey L Hildebrandt; Timothy Coskran; Shawn C Black; Dominique J Brees; Joan R Wicks; John D McNeish; Kevin G Coleman
Journal:  J Clin Invest       Date:  2003-07-03       Impact factor: 14.808

Review 10.  Minireview: Estrogenic protection of beta-cell failure in metabolic diseases.

Authors:  Suhuan Liu; Franck Mauvais-Jarvis
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.